MedTrace Logo

Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast Cancer

NCT02549677 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 294

Last updated 2022-10-27

No results posted yet for this study

Summary

The purpose of this study is to compare the safety and efficacy of epirubicin plus cyclophosphamide versus docetaxel plus cyclophosphamide in lymph node negative, estrogen receptor (ER) positive, human epithelial growth factor receptor 2 (HER2) negative breast cancer patients as adjuvant chemotherapy.

Conditions

  • Breast Neoplasms

Interventions

DRUG

Epirubicin

epirubicin, 90mg per square meter, every 3 weeks, day 1

DRUG

Docetaxel

docetaxel, 75mg per square meter, every 3 weeks, day 1

DRUG

cyclophosphamide

cyclophosphamide, 600mg per square meter, every 3 weeks, day 1

Sponsors & Collaborators

  • Ruijin Hospital

    lead OTHER

Principal Investigators

  • Li Zhu, doctor · Shanghai Jiao Tong University School of Medicine affiliated Ruijin Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2020-03-31
Completion
2020-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02549677 on ClinicalTrials.gov